# Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC

Source: https://onco.cc/trials/nct07743632/  
OnCo record `nct07743632` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of carboplatin, docetaxel, doxorubicin, cyclophosphamide and other drugs in triple-negative breast cancer, run by University of Kansas Medical Center, not yet recruiting.

## Summary

Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC is a phase 2, interventional study registered as NCT07743632 by University of Kansas Medical Center, with a registry enrolment figure of 110 participants, started 2026-09 and due to reach its primary completion in 2032-12. Interventions recorded: Carboplatin; Docetaxel; Doxorubicin; Cyclophosphamide; Ivonescimab. Conditions listed: Breast Cancer; Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Histologically confirmed cT1c-T3 N0 or cT1-T3 N1-N2 triple-negative breast cancer". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: NeoASPECT
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07743632
- Phase: 2
- Setting: Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC (NeoASPECT)
- Sponsor: University of Kansas Medical Center
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT07743632: https://clinicaltrials.gov/study/NCT07743632

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07743632.json